Table 2 Patient characteristics, treatment, and duration of follow up

Sex

M

F

M

M

M

F

M

M

M

F

Age at Dx, yrs

2.1

3.6

1.5

5.2

5.5

2.4

0.3

3.3

2.3

0.9

# of KD criteria

5

3

2

4

5

4

2

3

4

3

DOI at 1st IVIG tx

4

4

5

8

6

10

6

9

6

8

# of IVIG doses

3

2

3

3

2

2

2

2

2

2

# of IVMP pulses

2

3

1

3

3

0

0

0

0

0

DOI at start of main-tenance IVMP 2 mg/kg/day

23

31

20

16

27

10

6

9

6

8

Other immunomodulatory treatments

IFX ×2

IFX

IFX, CSA

CSA

IFX

Anakinra

None

None

None

None

DOI at CYC

23 and 32

34

20

25 and 37

31 and 38

25

21

13

10

16

# of CYC doses

2

1

1

2

2

1

1

1

1

1

Duration since dx at last follow up

11y 10mo

8 yr 11mo

0.5mo

3 yr 10mo

2 yr 11mo

3 yr 1mo

9mo

1 yr 10mo

3mo

2mo

Initial LAD z score

0.68

NL

6.08

4.66

1.77

13.06

2.96

10.7

13.4

1.85

Initial RCA z score

NL

NL

1.22

3.05

0.1

5.99

2.92

n/a

2.0

4.0

Max z score at CYC tx, LAD

27.2

29.57

31.27

17.3

19.9

20.35

5.39

10.12

15.5

4.7

Max z score at CYC tx, RCA

22.3

10.5

13.6

13

14.2

7.4

6.67

15.2

2.0

9.8

Max Z score at last follow up, LAD

13.5

1.13

31.1

0.56

5.0

13.9

1.02

1.16

7.7

0.4

Max Z score at last follow up, RCA

28.5

0.12

13.5

7.32

6.0

1.1

1.78

19.0

1.3

4.1